Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ECOG E3205: Phase II Trial of Cetuximab Plus Cisplatin, 5-Fluorouracil and Radiation in Immunocompetent Patients with Anal Carcinoma.

Trial Profile

ECOG E3205: Phase II Trial of Cetuximab Plus Cisplatin, 5-Fluorouracil and Radiation in Immunocompetent Patients with Anal Carcinoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Fluorouracil
  • Indications Anal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Jan 2017 Primary endpoint (Local Failure Rate at 3 Years) has been met, according to results published in the Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
    • 09 Jan 2017 Results published in the Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top